Daewon Pharm (003220) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Daewon Pharm (003220) has a cash flow conversion efficiency ratio of 0.111x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩30.61 Billion ≈ $20.75 Million USD) by net assets (₩274.58 Billion ≈ $186.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 003220 equity financing ratio to measure how much of total assets are equity-financed.
Daewon Pharm - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Daewon Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Daewon Pharm cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Daewon Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daewon Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sun Yad Construction Co Ltd
TW:1316
|
-0.040x |
|
Supergas Energy Ltd
TA:SPGE
|
0.058x |
|
AgriBank Securities JSC
VN:AGR
|
-0.271x |
|
Singha Estate Public Company Limited
BK:S-R
|
0.034x |
|
Technos S.A
SA:TECN3
|
0.012x |
|
Tile Shop Holdings Inc
NASDAQ:TTSH
|
-0.063x |
|
Platform Turizm Tasimacilik AS
IS:PLTUR
|
0.145x |
|
Eimco Elecon (India) Limited
NSE:EIMCOELECO
|
0.013x |
Annual Cash Flow Conversion Efficiency for Daewon Pharm (2011–2025)
The table below shows the annual cash flow conversion efficiency of Daewon Pharm from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see 003220 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩274.58 Billion ≈ $186.08 Million |
₩42.31 Billion ≈ $28.68 Million |
0.154x | +46.01% |
| 2024-12-31 | ₩284.58 Billion ≈ $192.85 Million |
₩30.04 Billion ≈ $20.35 Million |
0.106x | -46.09% |
| 2023-12-31 | ₩264.26 Billion ≈ $179.09 Million |
₩51.73 Billion ≈ $35.06 Million |
0.196x | +46.13% |
| 2022-12-31 | ₩248.77 Billion ≈ $168.58 Million |
₩33.33 Billion ≈ $22.58 Million |
0.134x | +30.54% |
| 2021-12-31 | ₩218.40 Billion ≈ $148.01 Million |
₩22.41 Billion ≈ $15.19 Million |
0.103x | -12.49% |
| 2020-12-31 | ₩212.77 Billion ≈ $144.19 Million |
₩24.95 Billion ≈ $16.91 Million |
0.117x | -22.67% |
| 2019-12-31 | ₩204.22 Billion ≈ $138.39 Million |
₩30.97 Billion ≈ $20.99 Million |
0.152x | -30.60% |
| 2018-12-31 | ₩183.20 Billion ≈ $124.15 Million |
₩40.03 Billion ≈ $27.13 Million |
0.219x | +761.41% |
| 2017-12-31 | ₩168.13 Billion ≈ $113.94 Million |
₩4.27 Billion ≈ $2.89 Million |
0.025x | -80.23% |
| 2016-12-31 | ₩162.01 Billion ≈ $109.79 Million |
₩20.79 Billion ≈ $14.09 Million |
0.128x | -26.10% |
| 2015-12-31 | ₩148.66 Billion ≈ $100.75 Million |
₩25.82 Billion ≈ $17.50 Million |
0.174x | +33.89% |
| 2014-12-31 | ₩134.51 Billion ≈ $91.16 Million |
₩17.45 Billion ≈ $11.82 Million |
0.130x | +29.76% |
| 2013-12-31 | ₩123.25 Billion ≈ $83.53 Million |
₩12.32 Billion ≈ $8.35 Million |
0.100x | -18.36% |
| 2012-12-31 | ₩112.92 Billion ≈ $76.53 Million |
₩13.83 Billion ≈ $9.37 Million |
0.122x | -29.04% |
| 2011-12-31 | ₩103.92 Billion ≈ $70.42 Million |
₩17.93 Billion ≈ $12.15 Million |
0.173x | -- |
About Daewon Pharm
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more